Nuvectis Pharma, Inc.
NVCT
$6.43
$0.6210.59%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -32.26% | 57.94% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 18.18% | 18.44% | |||
| Operating Income | -18.18% | -18.44% | |||
| Income Before Tax | -17.81% | -18.79% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -17.81% | -18.79% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -17.81% | -18.79% | |||
| EBIT | -18.18% | -18.44% | |||
| EBITDA | -- | -- | |||
| EPS Basic | -46.90% | -10.85% | |||
| Normalized Basic EPS | -10.79% | -10.89% | |||
| EPS Diluted | -46.90% | -10.85% | |||
| Normalized Diluted EPS | -10.79% | -10.89% | |||
| Average Basic Shares Outstanding | 6.33% | 7.17% | |||
| Average Diluted Shares Outstanding | 6.33% | 7.17% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||